Trial Profile
A phase I clinical study of PF-6928316
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2020
Price :
$35
*
At a glance
- Drugs PF 06928316 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Proof of concept
- 28 Jan 2020 According to a Pfizer media release, data from this study is expected in first half of 2020.
- 11 Sep 2018 New trial record